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ABSTRACT
In epithelial cells, β-catenin is localized at cell-cell junctions where it stabilizes 
adherens junctions. When these junctions are disrupted, β-catenin can translocate 
to the nucleus where it functions as a transcriptional cofactor. Recent research has 
indicated that PGE2 enhances the nuclear function of β-catenin through cyclic AMP. 
Here, we aim to study the role of the cyclic AMP effector Epac in β-catenin activation 
by PGE2 in non-small cell lung carcinoma cells.
We show that PGE2 induces a down-regulation of E-cadherin, promotes cell 
migration and enhances β-catenin translocation to the nucleus. This results in 
β-catenin-dependent gene transcription. We also observed increased expression 
of Epac1. Inhibition of Epac1 activity using the CE3F4 compound or Epac1 siRNA 
abolished the effects of PGE2 on β-catenin. Further, we observed that Epac1 and 
β-catenin associate together. Expression of an Epac1 mutant with a deletion in the 
nuclear pore localization sequence prevents this association. Furthermore, the scaffold 
protein Ezrin was shown to be required to link Epac1 to β-catenin.
This study indicates a novel role for Epac1 in PGE2-induced EMT and subsequent 
activation of β-catenin.
INTRODUCTION
Non-small cell lung carcinoma (NSCLC) is the most 
common variety of lung cancer and is the leading cause of 
cancer related deaths worldwide. One of the major causes 
for mortality is dissemination [1, 2] whereby, early in the 
metastatic cascade, carcinoma cells gradually lose their 
epithelial phenotype and acquire a motile, mesenchymal 
phenotype. This process is known as epithelial-to-
mesenchymal transition (EMT) [3]. In NSCLC cells, 
EMT can be induced by a variety of growth factors and 
other molecular mediators, including prostaglandin E2 
(PGE2) [4–8]. PGE2 is a potent inflammatory mediator 
produced by cyclooxygenase-2 (COX-2), whose levels 
are often found to be increased in many cancers, including 
lung carcinoma [9]. Elevated levels of PGE2 have been 
found to contribute to the induction of tumor angiogenesis, 
resistance to apoptosis, regulation of cell division, 
suppression of anti-tumor immunity and augmentation 
of cancer cell motility and invasiveness [10]. The use of 
selective COX-2 inhibitors has raised multiple concerns 
regarding its safety of long-term use in clinical trials [11]. 
Thus, further exploration of the pathways downstream 
of PGE2 receptor binding is important to elucidate the 
mechanisms of PGE2 signaling in cancer and could 
provide the basis for the development of novel therapy.
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Previous work from our group and others has shown 
that PGE2 results in the stabilization of the important 
oncogene β-catenin in cancer cells [12–14]. β-Catenin has 
a dual function in the cell; on one hand it is a component of 
the adherens junction, where it stabilizes E-cadherin/actin 
cytoskeleton binding, on the other hand, free cytosolic 
β-catenin can translocate to the nucleus. Although free 
cytosolic β-catenin levels are normally under tight control, 
accumulation of stabilized β-catenin eventually leads to its 
nuclear translocation, where it acts as a transcriptional co-
regulator. As such, nuclear β-catenin activates transcription 
of a broad range of target genes involved in survival and 
metastasis [15, 16]. In an in vivo model of colorectal 
carcinoma, it has been demonstrated that nuclear β-catenin 
and subsequent activation of TCF, a transcription factor 
commonly associated with nuclear β-catenin, increases 
the expression of the important EMT transcription factor 
zinc finger E-box binding homeobox 1 protein (ZEB1) 
[17], of which the expression has the most consistent 
inverse correlation with E-cadherin expression across 
different types of carcinomas [18]. This mechanism was 
recently confirmed in a pancreatic cancer model [19] and 
in an in vivo kidney model for EMT [20]. Thus, activation 
of β-catenin/TCF-dependent transcription (referred to 
as β-catenin-dependent transcription) can induce EMT, 
thereby down-regulating E-cadherin expression, further 
releasing β-catenin form the adherens junction, creating 
a positive feedback loop that attenuates cell-cell adhesion 
and reinforces EMT in transformed cells. The existence of 
this loop has been confirmed in a breast cancer stem cell 
model in which inhibition of β-catenin, using the β-catenin/
p300 inhibitor curcumin, breaks the loop, restoring 
E-cadherin expression and sequestering β-catenin at cell-
cell contacts [21]. In NSCLC cells, PGE2 has been found 
to induce EMT and enhance cell migration by augmenting 
ZEB1 and suppressing E-cadherin expression [4–8] via 
a mechanism requiring stabilization of β-catenin and 
activation of β-catenin-dependent transcription [4, 7, 8].
PGE2 exerts it’s intracellular actions by binding to 
membrane bound E-type prostanoid receptors, of which type 
2 and type 4 are known to couple to Gαs and thereby increase 
intracellular cyclic AMP. There are two known effectors of 
cyclic AMP; namely protein kinase A (PKA) and exchange 
protein directly activated by cyclic AMP (Epac). There are 
two Epac isoforms, Epac1 and Epac2, which have distinct 
tissue expression patterns [22]. In addition, Epac activity is 
regulated through interaction with other intracellular proteins, 
such as Ezrin-radixin-moesin (ERM) proteins at the cell 
membrane [23–25] and the nucleoporin, Ran binding protein 
2 (RanBP2), at the nuclear membrane [26–29]. Interestingly, 
a body of recent evidence indicates that Epac is required for 
cancer cell migration [30–36].
Here, we aim to study the contribution of Epac to 
PGE2 and β-catenin-induced EMT and cell migration in 
NSCLC cells.
RESULTS
PGE2 induces epithelial-to-mesenchymal 
transition
In multiple cancer cell models, including NSCLC 
cells, PGE2 has been found to induce EMT [4, 5, 7, 8, 
41]. To study the role of PGE2 in NSCLC, we used A549 
as a cell model, which is of alveolar epithelial origin. To 
confirm PGE2-induced EMT in A549 cells, cells were 
incubated with 16,16-dimethyl-PGE2 (PGE2) for 18 hours. 
Subconfluent cultures showed decreased mRNA and protein 
expression of the epithelial marker E-cadherin after PGE2 
treatment (Figure 1A-1B). Expression of the important 
regulatory EMT transcription factor and β-catenin target 
gene, ZEB1, was found to be increased by PGE2 treatment 
(Figure 1A). Interestingly, after scratch-wounding of a 
confluent monolayer, PGE2 treatment resulted in decreased 
E-cadherin protein expression, primarily in cells on an edge, 
while cells that were fully incorporated in the epithelial 
structure were less affected (Figure 1C-1D). In addition, 
immunofluorescence staining revealed that PGE2 does not 
increase overall expression of the mesenchymal marker 
N-cadherin, while intracellular distribution is altered with 
N-cadherin being less present at the cell membrane (Figure 
1E-1F). However, expression of the mesenchymal marker 
vimentin was increased. This confirms PGE2 as an EMT 
inducer in A549 cells that are not fully incorporated in an 
epithelial structure.
PGE2 enhances β-catenin nuclear translocation 
and β-catenin-dependent transcription
E-cadherin and β-catenin are both present in 
multiprotein complexes, known as the adherens junctions, 
which mediate cell-cell contacts. When E-cadherin is 
downregulated, β-catenin can diffuse freely in the cytosol 
and nucleus and promote gene expression [16].
We have shown in other cell models, that PGE2 
stabilizes β-catenin [14]. We therefore studied the role 
of β-catenin in PGE2 induced EMT in A549 cells. When 
we incubated a subconfluent culture of A549 cells with 
PGE2, we observed decreased expression of β-catenin 
at areas of cell-cell contact (Figure 2A). Accordingly, 
we observed increased localization of β-catenin within 
the cell nucleus (Figure 2A-2B), indicating membrane 
to nucleus translocation of β-catenin. Nuclear β-catenin 
is a well-known co-activator of several transcriptional 
programs that are involved in cancer. Nuclear β-catenin 
activates gene expression primarily through associating 
with the TCF/Lef family of transcription factors. To assess 
β-catenin-dependent transcription in response to PGE2, 
A549 cells were transfected with a TCF luciferase reporter 
gene (TOPFlash) containing multiple TCF binding sites or 
with a reporter deficient in TCF binding sites (FOPFlash). 
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Figure 1: Effect of PGE2 on EMT in A549 cells. A. Gene expression of E-cadherin and ZEB1 following 18 hours stimulation with 
PGE2 (10 μg/ml). B. Representative western blot image of E-cadherin expression in a subconfluent culture of A549 cells stimulated for 18 
hours with PGE2. C. Immunofluorescence images of E-cadherin after18 hours stimulation with PGE2. The white line indicates the migrating 
border in a scratch wound assay. White arrows in indicate areas of cell-cell contact, which are decreased in cells on the migrating border 
in the right image. Scale bar represents 20 μm. D. Quantification of E-cadherin expression in migrating border cells and cells incorporated 
in an epithelial sheet. Each points represents the average integrated density value (IDV) of 20 cells. E. Immunofluorescence images of 
N-cadherin/E-cadherin and Vimentin/E-cadherin after18 hour stimulation with PGE2. Scale bar represents 20 μm. Data represent mean ± 
SEM of 5 separate experiments. # p < 0.05, ## p < 0.01 compared to DMSO treated cells. *** p < 0.001 between the indicated groups. F. 
Quantification of N-cadherin and Vimentin expression in cells treated for 18h with DMSO or PGE2.
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Figure 2: Effect of PGE2 on β-catenin nuclear translocation and transcriptional activity in A549 cells. A. Immunofluorescence 
images of β-catenin after 18 hours stimulation with PGE2. White arrows indicate areas of cell-cell contact. Presence of β-catenin at these 
areas is decreased in PGE2-treated cells, whereas nuclear localization is increased. Scale bar represents 40 μm. B. Quantification of β-catenin 
nuclear localization. Each points represents the average integrated density value (IDV) of 20 cells. C. TCF luciferase gene reporter assay 
of β-catenin transcriptional activity (TOPFlash) after 18 hours stimulation with PGE2. D. TOPFlash assay of cells co-incubated with 
antagonists of the EP4 receptor (L161,982; 3 μM), the EP1 and EP2 receptor (AH6809; 10 μM) or PI3 kinase (LY29004, 50 μM). E. 
Measurement of cyclic AMP production. Cells were co-treated with IBMX to inhibit phosphodiesterase activity. Forskolin (10 μM) was 
used as a positive control for cyclic AMP production by adenylyl cyclase. Data represent mean ± SEM of 5-9 separate experiments. # p 
< 0.05, ## p < 0.01, ### p < 0.001 compared to DMSO treated cells. * p < 0.05, ** p < 0.01 *** p < 0.001 between the indicated groups.
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PGE2 induced TCF reporter gene expression, as indicated 
by an increased TOP/FOP ratio (Figure 2C).
PGE2 exerts its effects through activation of E-type 
prostanoid receptors. A549 cells mainly express the 
EP2 and EP4 receptor subtype which are Gαs-coupled 
and enhance formation of intracellular cyclic AMP. To 
determine which receptor is involved in PGE2-induced 
β-catenin-dependent transcription, EP receptors were 
blocked using the EP4 antagonist L-161,982 and the 
EP2 antagonist AH6809. AH6809 completely prevented 
PGE2-induced β-catenin-dependent transcription while 
L-161,982 had no effect (Figure 2D). In addition, PI3 
kinase, an important lipid kinase which can be activated 
downstream of EP receptors, also contributes to β-catenin 
stabilization [12]. However, pharmacological inhibition 
of PI3 kinase using LY29004 had no effect on PGE2-
induced β-catenin-dependent transcription in A549 cells, 
demonstrating that the effects of PGE2 are mediated 
through the Gαs-coupled EP2 receptor and cyclic AMP. 
Indeed, when we stimulated cells with PGE2, we observed 
enhanced cyclic AMP synthesis, which was attenuated by 
pretreatment with AH6809 (Figure 2E).
Epac1 is required for PGE2-induced β-catenin 
activation
Importantly, while expression of the cyclic AMP 
effector Epac1 was relatively low under basal conditions, 
we observed that cells undergoing PGE2-induced EMT 
displayed increased expression of Epac1 (Figure 3A). 
Expression of Epac2 was unaltered. We therefore 
questioned if Epac1 is involved in PGE2-induced 
β-catenin nuclear translocation and transcriptional 
activity. To this aim, we used the Epac1 subtype specific 
inhibitor CE3F4 [37]. PGE2-induced β-catenin nuclear 
translocation was significantly decreased in cells co-
incubated with CE3F4, indicating that Epac1 is required 
(Figure 3B-3C). In accordance with this observation, we 
demonstrated that PGE2-induced β-catenin-dependent 
transcription was completely abolished in cells incubated 
with CE3F4, while the Epac2 subtype specific inhibitor 
ESI-05 [38], had no effect (Figure 3D). Furthermore, 
PGE2-induced expression of the β-catenin target gene and 
EMT regulator, ZEB1, was attenuated in cells incubated 
with CE3F4 (Figure 3E). To confirm these observations 
we applied a siRNA approach to knock down Epac1 
expression in A549 cells. PGE2-induced β-catenin-
dependent transcription was significantly impaired 
in Epac1 siRNA transfected cells, compared to non-
targeting siRNA transfected cells (Figure 4A). In Epac1 
siRNA transfected cells, PGE2 was no longer able to 
increase Epac1 expression (Figure 4B-4C). Accordingly, 
PGE2-induced expression of ZEB1 was also abolished in 
Epac1 siRNA transfected cells (Figure 4B). Collectively, 
these findings indicate that Epac1 is required for PGE2-
induced β-catenin-dependent transcription.
Epac1 is required for PGE2-induced cell 
migration
Functionally, cells undergoing EMT show increased 
migratory behavior. When we created a wound area 
in a confluent monolayer by carefully scratching the 
monolayer, cells stimulated with PGE2 started migrating 
inwards the wounded area (Figure 5A). Cells that were on 
the leading edge showed a different, more mesenchymal 
phenotype, when compared to cells embedded in the 
monolayer, which appeared epithelial. This confirms our 
earlier observations in which we found that PGE2 only 
affects cells that are on the leading edge (Figure 1C-1D). 
In cells co-treated with the Epac1 inhibitor CE3F4 or 
cells transfected with Epac1 siRNA, PGE2 was no longer 
able to promote migration (Figure 5B). Additionally, in a 
real time assay for cell migration using the xCELLigence 
platform [42], PGE2 increased migration of cells, which 
was abolished in cells co-treated with CE3F4 (Figure 5C).
Nuclear pore localization of Epac1 is required 
for PGE2-induced β-catenin activation
Epac1 has been shown to translocate to perinuclear 
regions following activation by cyclic AMP [26–29]. 
The nuclear localization of Epac1 requires the catalytic 
domain of Epac1 binding to the nuclear pore protein 
RanBP2. When we overexpressed wildtype Epac1 
(Figure 6C), we also found a clear nuclear localization 
of Epac1 (Figure 6A). In contrast, expression of Epac1 
with a deletion mutation in the catalytic domain (Δ764-
838) renders the mutant Epac1 unable to correctly localize 
to the nucleus (Figure 6A). As β-catenin also needs to 
translocate to the nucleus in order to activate β-catenin-
dependent transcription, we hypothesized that correct 
localization of Epac1 is required for nuclear translocation 
of β-catenin. Indeed, cells expressing Epac1 Δ764-838 did 
not show PGE2-induced β-catenin-dependent transcription 
(Figure 6B). Interestingly, when we performed a co-
immunoprecipitation to confirm a molecular interaction 
between Epac1 and β-catenin, we found that Epac1 
co-immunoprecipitated with β-catenin, but that this 
interaction was almost absent in cells transfected with the 
mutant Epac1 Δ764-838 (Figure 6D-6E). This indicates 
that the interaction between Epac1 and β-catenin may 
only occur when both proteins are correctly localized to 
the nucleus. Accordingly, PGE2 no longer increased the 
expression of ZEB1 in cells transfected with the mutant 
Epac1 Δ764-83 (Figure 6E).
Ezrin links Epac1 to β-catenin during PGE2-
induced β-catenin activation
Direct binding of Epac1 and β-catenin has not been 
described before. Nonetheless, the A-kinase anchoring 
protein family member Ezrin is a scaffold protein which 
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Figure 3: Role of Epac1 in PGE2-induced β-catenin nuclear translocation in A549 cells. A. Gene expression of Epac1, but 
not Epac2, is increased by PGE2. B. Quantification of β-catenin nuclear localization. Each points represents the average integrated density 
value (IDV) of 20 cells. C. Immunofluorescence images of β-catenin in cells treated with PGE2. Co-incubation with a specific Epac1 
antagonist (CE3F4, 20 μM) abolished PGE2-induced β-catenin nuclear translocation. Scale bar represents 40 μm. D. TOPFlash assay of 
cells co-incubated with specific antagonists for Epac1 (CE3F4) and Epac2 (ESI-05; 10 μM). E. PGE2-induced gene expression of ZEB1 is 
attenuated by co-incubation with CE3F4. Data represent mean ± SEM of 5-9 separate experiments. # p < 0.05, ### p < 0.001 compared to 
DMSO treated cells. *** p < 0.001 between the indicated groups.
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has been shown to bind E-cadherin, β-catenin and Epac1 
[23, 43]. In addition, Ezrin is involved in migration of 
carcinoma cells, including NSCLC cells [24, 44–46]. 
Therefore, we questioned whether Ezrin might be a 
common adaptor protein that mediates the interaction 
between β-catenin and Epac1 in cells undergoing PGE2-
induced EMT. To study the role of Ezrin, we applied 
a siRNA knockdown approach (Figure 7A). In Ezrin 
siRNA-treated cells, PGE2-induced β-catenin-dependent 
transcription was abolished (Figure 7B). In addition, we 
observed co-immunoprecipitation of Ezrin and Epac1 
(Figure 7C-7D). Cells treated with Ezrin siRNA, co-
immunoprecipitation of Epac1 and β-catenin was no 
longer observed, indicating that Ezrin is required for the 
association of Epac1 and β-catenin.
DISCUSSION
The contribution of PGE2 to EMT in NSCLC cells has 
previously been reported [4–8]. Our findings confirm that 
PGE2 induced a marked downregulation of E-cadherin and 
activation of β-catenin, primarily at cells on the migrating 
Figure 4: Epac1 knockdown prevents PGE2-induced β-catenin transcriptional activity in A549 cells. A. TOPFlash assay 
of cells transfected with non-targeting siRNA or Epac1 siRNA for 48h and subsequent PGE2 treatment. B. Gene expression of Epac1 
and ZEB1 in cells transfected with Epac1 siRNA in combination with PGE2 treatment. C. Knockdown of Epac1 protein in Epac1 siRNA 
transfected cells. Data represent mean ± SEM of 5-9 separate experiments. ## p < 0.01, ### p < 0.001 compared to non-targeting siRNA 
transfected cells. ** p < 0.01, *** p < 0.001 between the indicated groups.
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edge, subsequently leading to cell migration. It has been 
reported that PGE2 increases levels of stabilized β-catenin 
[5, 7, 8] and activation of β-catenin-dependent transcription 
[5]. In addition, emphasizing the importance of β-catenin 
in PGE2-induced EMT in NSCLC cells, pharmacological 
inhibition of β-catenin with the FH535 compound has been 
shown to completely abolish the effects of PGE2 on EMT 
[7, 8]. EMT is under tight control of a series of transcription 
Figure 5: Role of Epac1 in PGE2-induced cell migration of A549 cells. A. Representative images of a wound healing assay 
24 hours post scratch. The black lines indicate borders of scratch on 0 hours. The white lines indicate borders of scratch on 24 hours of 
DMSO treated cells. B. Quantification of wound closure of PGE2 treated cells in co-incubation with the Epac1 antagonist CE3F4 or in 
Epac1 silenced cells. C. xCELLigence assay of real-time cell migration of cells stimulated with PGE2 (left panel) or in co-incubation with 
the Epac1 antagonist CE3F4. x-Axis indicates time in hours. Data represent mean ± SEM of 6 separate experiments. ## p < 0.01 compared 
to DMSO treated cells. * p < 0.05 between the indicated groups.
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Figure 6: Expression of a mutant Epac1 with a deletion of the 764-838 domain has aberrant localization and prevents 
PGE2-induced β-catenin transcriptional activity in A549 cells. A. Immunofluorescence images of FLAG-tagged Epac1 wildtype 
(WT) and Epac1 Δ764-838. White arrows indicate absence of nuclear localization for the Epac1 deletion mutant. Scale bar represents 40 μm. 
B. TOPFlash assay of cells transfected with Epac1 Δ764-838 and subsequent PGE2 treatment. C. Western blot image confirming successful 
expression of FLAG-tagged Epac1 Δ764-838. D. Western blot images of a FLAG immunoprecipitation showing co-immunoprecipitation 
of Epac1 and β-catenin in FLAG-Epac1 WT transfected cells, which is attenuated in and FLAG-Epac Δ764-838 transfected cells. For input 
we used 5% of the amount of protein used for co-immunoprecipitation. E. Quantification of β-catenin co-immunoprecipitation with FLAG 
immunoprecipitation. β-Catenin was normalized for the amount of FLAG immunoprecipitated. Data represent mean ± SEM of 3-9 separate 
experiments. # p < 0.05, ### p < 0.001 compared to empty vector transfected cells. § p < 0.05 compared to FLAG-Epac1 WT transfected 
cells. *** p < 0.001 between the indicated groups.
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factors, including ZEB1, which regulate the expression of 
proteins involved in cell-cell adhesion, extracellular matrix 
composition including matrix metalloproteases, and cell 
migration. In NSCLC cells, PGE2 has been shown to increase 
expression of the EMT regulator ZEB1 [4, 5]. In a recent 
study, inhibition of β-catenin-dependent transcription renders 
NSCLC cells unable to migrate [47]. Our observations 
confirm that expression of ZEB1 is increased by PGE2 
and coincides with nuclear translocation of β-catenin and 
activation of β-catenin-dependent transcription.
Figure 7: Ezrin knockdown prevents PGE2-induced β-catenin transcriptional activity in A549 cells. A. Knockdown of 
Ezrin protein in Ezrin siRNA transfected cells. B. TOPFlash assay of cells transfected with non-targeting siRNA or Ezrin siRNA for 
48 hours and subsequent PGE2 treatment. C. FLAG co-immunoprecipitation of Epac1, β-catenin and Ezrin in FLAG-Epac1 WT transfected 
and Ezrin silenced cells. For input we used 5% of the amount of protein used for co-immunoprecipitation. D. Quantification of β-catenin 
and Ezrin co-immunoprecipitation with FLAG immunoprecipitation. β-Catenin and Ezrin were normalized for the amount of FLAG 
immunoprecipitated. Data represent mean ± SEM of 3-9 separate experiments. ## p < 0.01 compared to non-targeting siRNA transfected 
cells. § p< 0.05, §§ p < 0.01 compared to scrambled siRNA transfected cells. *** p < 0.001 between the indicated groups.
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We and other have previously shown that PGE2, 
through activation of cyclic AMP, is responsible for 
activating β-catenin, thus making the Gαs-coupled EP2 
and EP4 receptor the most likely candidates [14]. Here, 
we observed no effect of specific antagonism of the 
EP4 receptor on PGE2-induced β-catenin-dependent 
transcription, whereas antagonism of the EP2 receptor 
completely abolished the effect of PGE2. This finding is 
contrary to earlier work from others who identified the 
EP4 receptor as the main contributor in PGE2-induced 
cell migration of NSCLC cells, possibly through a 
mechanism involving PI3 kinase and Akt [5, 6]. However, 
we observed no effect of PI3 kinase inhibition on PGE2-
induced activation of β-catenin-dependent transcription, 
indicating that this EP4/PI3 kinase pathway was not linked 
to β-catenin activation in our cell model. A recent study 
investigating the effect of PGE2 on normal bronchial 
epithelial cells, found that PGE2 induces migration in 
pre-EMT cells, while in post-EMT cells, PGE2 decreases 
migration [41]. This study showed that this change in 
response to PGE2 was accompanied by a reduction in 
expression of EP2 and EP4 receptors in post-EMT. Specific 
agonism of the EP2 and EP4 receptor mimicked the effects 
of PGE2, confirming our findings that the Gαs-coupled EP 
receptors are crucial for PGE2-induced EMT.
Earlier studies by us and others have indicated 
that PGE2 activates β-catenin-dependent transcription 
via cyclic AMP [13, 14, 48–52]. When we investigated 
expression of the cyclic AMP effector Epac, we observed 
increased expression of the Epac1 subtype by PGE2. 
Similar to our findings, studies on prostate cancer cell 
lines [53], squamous cell carcinoma [54] and umbilical 
cord derived mesenchymal stem cells [55] have also 
reported increased expression of Epac1 in response to 
PGE2. The role of Epac in regulation of migration and the 
adherens junction in lung has recently been extensively 
described in extensive reviews [22, 56]. Importantly, 
several recent studies have implicated Epac1 in the 
activation of cancer cell migration and metastasis [35, 36, 
57]. In addition, using specific pharmacological inhibitors, 
it was demonstrated that Epac1 is required for migration 
and metastasis of pancreatic cancer, both in vitro [32, 58] 
and in vivo [30].
We observed that specific inhibition of Epac1 
using the pharmacological inhibitor CE3F4 [37] not only 
decreased migration of NSCLC cells, but also abolished 
PGE2-induced nuclear accumulation of β-catenin, 
activation of β-catenin-dependent transcription and 
expression of the EMT regulator ZEB1. Using Epac1 
siRNA, we were able to confirm that these observations 
were due to Epac1 inhibition and not due to off-target 
effects of the compound.
Epac1 can directly bind to the nuclear pore protein 
RanBP2 at the nuclear membrane [26–29]. The recent 
identification of the sequence in the CDC25-HD domain 
of Epac1 responsible for the binding [28] provided us 
with a tool to study the role of Epac1 localization to the 
nuclear pore in PGE2-induced activation of β-catenin. 
In this study we were able to show that blocking Epac1 
localization to the nuclear pore, using an Epac1 mutant 
that lacks this sequence [28], abolished PGE2-induced 
activation of β-catenin-dependent transcription. Studies on 
the activity of Epac1 binding to RanBP2 have provided 
contradictory results. One study showed decreased activity 
[28], while another showed increased activity [26]. Thus, 
the exact role of Epac1 at the nuclear envelope or nuclear 
pore is still controversial and warrants further exploration. 
Additionally, we observed co-immunoprecipitation 
between Epac1 and β-catenin, a process attenuated 
in cells expressing the nuclear pore-deficient Epac1 
mutant, indicating that the interaction between Epac1 
and β-catenin likely occurs at the nuclear pore complex. 
However, direct interaction between Epac1 and β-catenin 
remained questionable. Thus, we hypothesizes that an 
adaptor protein brings together Epac1 and β-catenin. 
One likely candidate adaptor protein is Ezrin, which 
has been shown to bind E-cadherin, β-catenin [59] and 
Epac1 [23]. Importantly, Ezrin depleted NSCLC cells did 
not show cell spreading in response to Epac1 activation, 
indicating that Ezrin is critical in this process [24]. Ezrin 
can be phosphorylated by a plethora of kinases, including 
PKA which phosphorylates Ezrin on Thr567, thereby 
promoting an open conformation [24, 60]. Thus PKA, 
which is also activated by PGE2 downstream of the EP2 
and EP4 receptor can activates Ezrin directly. In addition, 
the open conformation of Ezrin can bind Epac1 at the 
N-terminal region [23, 24]. Ezrin expression correlates to 
an invasive phenotype in several carcinomas, including 
lung carcinoma, and in vitro, knockdown of Ezrin reduced 
the proliferation, migration, and invasion of cancer cells 
[44–46, 61–63]. Further, reduced cytosolic β-catenin and 
increased E-cadherin were observed which was restored 
by Ezrin knockdown. Together, this led us to believe 
that Ezrin could be the factor bringing together Epac1 
and β-catenin during PGE2-induced EMT in NSCLC 
cells. Indeed, knockdown of Ezrin using siRNA strongly 
reduced PGE2-induced β-catenin-dependent transcription 
and abolished co-immunoprecipitation of Epac1 and 
β-catenin, indicating that indeed Ezrin is required for the 
Epac1 and β-catenin association in NSCLC cells.
The critical role of PGE2 and β-catenin in 
tumorigenesis has long been recognized. Altered 
expression and activity of components of cyclic AMP 
signaling are common in various cancers. While PKA has 
received most attention, the role of Epac1 is emerging 
[31, 64]. Evidence on Epac1 in migration and metastasis 
is accumulating and this study provides the first clues on 
the involvement of Epac1 in transducing the signal from 
PGE2 to β-catenin in cancer cell migration. Together with 
other studies, our current findings indicate that specific 
targeting of Epac1 could present a novel target in anti-
cancer therapy that warrants further exploration. The 
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recent development of specific agonists and antagonists 
for the Epac isoforms can greatly enhance research on the 
role of Epac in cancer for the coming years.
MATERIALS AND METHODS
Reagents
16,16-dimethyl-PGE2, L161,982, AH6809 and 
Forskolin were from Tocris Bioscience (Bristol, UK). 
Ly29004 was from Cell Signaling (Beverly, MA). The 
pharmacological inhibitor for Epac1, CE3F4 was developed 
by F. Lezoualc’h [37]. The pharmacological inhibitor for 
Epac2, ESI-05 was developed by X. Cheng [38]. TRIzol® 
was from Thermo Fisher Scientific (Waltham, MA). All 
other chemicals were of analytical grade.
Cell culture
The human alveolar NSCLC cell line A549 was 
obtained from ATCC (Manassas, VA, USA). Cells were 
maintained in RPMI 1640 supplemented with 10% v/v 
heat-inactivated FCS and antibiotics (penicillin 100 U/
ml, streptomycin 100 μg/ml) in a humidified atmosphere 
of 5% (v/v) CO2 at 37°C. Cells were washed with HBSS 
(400 mg/l KCl, 60 mg/l KH2PO4, 8 g/l NaCl, 350 mg/l 
NaHCO3, 50 mg/l Na2HPO4.H2O, 1 g/l glucose, pH 7.4), 
dissociated from plates with trypsin/EDTA and seeded 
in appropriate cell culture plates. Cells were maintained 
at subconfluence but were allowed to achieve sufficient 
confluence to allow the formation of epithelial sheets. 
Cells were maintained in 0.5% (v/v) FCS 24 hours before, 
and during, stimulation, since 0% (v/v) FCS has been 
shown to increase production of PGE2 in A549 cells [39].
Transfection
Cells were grown to 60% confluence and were then 
transfected using TransIT-X2 transfection reagent (Mirus 
Bio, Madison, WI) in a 2:1 reagent:DNA ratio in complete 
growth medium. Cells were transfected with plasmid DNA 
(Per Ø 10 cm dish: 4.5 μg TOPFlash, 4.5 μg FOPFlash, 
0.5 μg renilla luciferase (Upstate Biotechnology, 
Charlottesville, VA), 5.0 μg pFLAG-CMV2-Epac1 WT, 
5.0 μg pFLAG-CMV2-Epac1 Δ764-838 or siRNA (50 nM 
Epac1 siRNA, 50 nM Ezrin siRNA (ON-TARGET Plus 
SMARTpool, Dharmacon GE, Lafayette, CO).
TOPFlash assay
β-Catenin dependent transcriptional activity was 
assayed using the TCF-dependent luciferase reporter 
TOPFlash. TOPFlash or its negative control FOPFlash 
transfected cells were subjected to PGE2 stimulation for 
24 hours, after which luciferase activity was assayed using 
the Dual Reporter luciferase assay system (Promega, 
Madison, WI). Transfection with renilla luciferase 
was used as a transfection and loading control. During 
transfection with TOPFlash or FOPFlash plasmids, 
growth medium contained 0.5% FCS because higher 
concentrations induce nuclear translocation of β-catenin.
Immunofluorescence
Cells were grown on LabTek II Chamber Slides 
(Thermo Fisher Scientific, Marietta, OH, USA) and 
then fixed with 4% (w/v) PFA/4% (w/v) sucrose 
and permeabilized with 0.3% (w/v) Triton X-100 in 
cytoskeletal buffer (10 mM Tris, 150 mM NaCl, 5 mM 
EGTA, 5 mM MgCl2, 5 mM glucose, pH 6.1). Cells 
were then blocked using 1% (w/v) BSA and 2% (v/v) 
donkey serum in CytoTBS-T (20 mM Tris, 154 mM 
NaCl, 2 mM EGTA, 2 mM MgCl2, 0.1% v/v Tween-20, 
pH 7.2). β-Catenin, E-cadherin, Vimentin and N-cadherin 
antibodies were applied overnight after which, secondary 
FITC-conjugated donkey anti-rabbit IgG or Cy3-
conjugated donkey anti-mouse IgG (Jackson Laboratories, 
Bar Harbor, ME, USA) were applied for 3h. Cell nuclei 
were visualized with 1 μg/ml Hoechst 33342 (Invitrogen, 
Carlsbad, CA, USA). Slides were mounted with ProLong® 
Gold Antifade Reagent (Life Technologies, Marietta, OH, 
USA). Images were captured with a Leica DM4000 B 
Fluorescence microscope (Leica Microsystems, Wetzlar, 
Germany) equipped with a Leica DFC 345 FX camera.
Quantification of immunofluorescence
Protein expression was quantified using ImageJ 
software. 5 immunofluorescence pictures, of areas chosen 
at random, from each of 4 independent experiments were 
analyzed. In each picture, signal intensity was measured 
inside a region of interest (ROI) (ROI: E-cadherin – 
membrane, N-cadherin – whole cell, vimentin – cytoplasm, 
β-catenin – nucleus). For β-catenin nuclear accumulation, 
the ROI was determined by creating a dual channel overlay 
of β-catenin and Hoechst 33342 staining, selecting only the 
areas positive for Hoechst 33342 and subsequently splitting 
the channels in the remaining image to create one image per 
channel. For each ROI, the integrated density value (IDV) 
was determined using ImageJ. IDV’s were normalized for 
the average IDV of the control condition.
Isolation of mRNA and real-time PCR analysis
Total mRNA extraction was performed using 
TRIzol® extraction and cDNA was then obtained using 
reverse transcription by AMV Reverse Transcriptase Kit 
(Promega, Madison, WI). qPCR was performed with the 
Illumina Eco Personal qPCR System (Westburg, Leusden, 
The Netherlands). Cycle parameters (30s each) were: 
denaturation at 94°C, annealing at 60°C and extension 
at 72°C. Target genes were normalized to the geometric 
mean of reference genes GAPDH and 18S. Primer 
sequences are listed in Table 1.
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Immunoblotting
Cells were lysed in ice-cold RIPA buffer 
supplemented with phosphatase and protease inhibitors 
(1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml 
pepstatin A, 1 mM Na3VO4, 1 mM NaF, 1.06 μg/ml 
β-glycerophosphate). Equal amounts of protein were 
subjected to electrophoresis on polyacrylamide gels and 
transferred to nitrocellulose membranes. Membranes 
were blocked with Roti-Block (Carl Roth, Karlsruhe, 
Germany). Protein expression was determined by 
specific primary and horseradish peroxidase (HRP)-
conjugated secondary antibodies in Tris-buffered saline 
with 0.1% (v/v) Tween-20. Antibodies used are listed 
in Table 2. Protein expression was visualized by ECL 
in the Syngene G:BOX HR iChemi gel documentation 
system (Syngene; Cambridge, UK). Band intensities 
were quantified by densitometry using ImageJ 
software.
Cyclic AMP assay
Cells were pretreated for 30 minutes with 1 
mM 3-Isobutyl-1-methylxanthine (IBMX) to inhibit 
phosphodiesterase-mediated breakdown of cyclic AMP 
and AH6809. After pretreatment, cells were stimulated 
with PGE2 or Forskolin for 5 minutes. Cyclic AMP 
synthesis was determined by using the cyclic AMP 
assay kit from BioTrend Chemicals (Cologne, Germany) 
according to manufacturer’s prescriptions.
Co-Immunoprecipitation
Cells were lysed in non-denaturing ice-cold 
lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, pH 7.6) 
supplemented with protease inhibitors (1 μg/ml leupeptin, 
1 mM PMSF, 1mM Na3VO4, 1 mM NaF, 1.06 μg/ml 
β-glycerophosphate). Lysates were centrifuged for 10 
min at 14,000xg at 4°C and supernatants were pre-
cleared with protein A/G agarose beads. Subsequently, 
500 μg protein was incubated was 1 μg of primary 
antibody or control IgG for 16 hours at 4°C with gentle 
rocking. Subsequently, protein A/G agarose beads were 
added for an additional 2 hours. Beads were collected by 
centrifugation and washed 5 times in lysis buffer. Beads 
were then boiled for 5 min at 95°C in denaturing SDS 
buffer before SDS-PAGE. Co-immunoprecipitated protein 
was (semi) quantified by densitometry using ImageJ 
software. Co-immunoprecipitated proteins were corrected 
for efficiency of immunoprecipitation by normalizing for 
immunoprecipitated FLAG.
Wound assay
A confluent monolayer was gently scratch wounded 
with a pipette tip in triplicate. After washing away the 
detached cells, cells were allowed to migrate in the wound 
area in the absence or presence of PGE2 and inhibitors. 
The wound area was photographed immediately after a 
scratch and then after 6 hours and 24 hours stimulation. 
Open wound area relative to non-stimulated cells was 
quantified using TScratch software [40].
xCELLigence transwell migration
Label-free, real-time quantification of cell 
migration was assayed using the xCELLigence transwell 
migration system using CIM-16 plates (RTCA DP, ACEA 
Biosciences, San Diego, CA). Briefly, 5% (v/v) FCS 
growth medium was added as a chemoattractant in the 
bottom. Serum-free media was added to the top chamber 
and plates were placed in the system for equilibration. 
Cells were detached using TrypLE Express enzyme to 
protect cell surface proteins (Thermo Fischer Scientific, 
Waltham, MA) and 30,000 cells were added to the top 
chamber in serum-free media containing PGE2 and 
inhibitors. Cells were allowed to adhere for 30 min at 
room temperature before being placed in the system 
for 24 hours in a 5% (v/v) CO2 humidified atmosphere 
at 37°C. The system was set to take a cell index 
measurement at 5 min intervals.
Statistics
Data represents means ± SEM, from n separate 
experiments. Normality and equal variance were 
evaluated by Shapiro-Wilk test and F-test. Statistical 
significance of differences was evaluated by Student’s 
t-test, 1-sample t-test or 1-way or 2-way ANOVA 
followed by Tukey’s multiple comparisons test, where 
appropriate.
Table 1: Primer sequences
Gene Forward Reverse
RAPGEF3 (Epac1) GGAAGAACATGGCAAAGTGG ATGAGCACTGGAATCTGGTC
RAPGEF4 (Epac2) AAGAACCATCAGGATGTCCG TGTGGACTGGAGACAAACTG
ZEB1 CTTAGGACAAAAAGTAGGCG GAACAGGAATCACAGCATAC
CDH1 (E-cadherin) TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC
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